Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Conference, Trade Show, Advisory

OrganaBio to exhibit at 2022 ASH Annual Meeting and Exposition


Attending ASH22 American Society of Hematology between December 10-12?

Our unique, flexible model combines proprietary and scalable tissue sourcing with advanced processing and characterization of perinatal and adult peripheral blood (including umbilical cord blood and leukopaks). OrganaBio can tailor our products and services to your evolving needs, such as rapidly manufacturing a variety of isolated cells such as CD34+ HSCs, T, B & NK Cells, and macrophages from tissues for pre-clinical research use as well as in the manufacturing of clinical-grade cell therapies. Visit us at booth 2143 or schedule a time to meet with our VP of Corporate Development, Dr. Priya Baraniak: https://meetings.hubspot.com/priya21/meet-with-dr-priya-baraniak


These press releases may also interest you

at 04:00
Trakx, an emerging global fintech company providing thematic Crypto Tradable Indices ("CTIs"), today announced the launch of the Trakx USDc Earn CTI powered by OpenTrade that is designed to allow users to easily generate high risk-adjusted returns on...

at 04:00
Aiming at offering greater enjoys for customers with products that have less harmful effects on the environment and more benefits on sustainable power generation, Astronergy upgraded its residential products ? ASTRO N7s again with less redundant...

at 04:00
Aetina, a leading Edge AI solution provider, announced the launch of the Aetina IA380E-QUFL at Embedded World 2024 in Nuremberg, Germany. This groundbreaking product is a small form factor PCIe graphics card powered by the high-performance Intel Arc...

at 04:00
A novel ice hockey puck with an integrated chip is revolutionising the world of sport. The Swiss ice hockey puck, known as an "Eisgenoss", which is being issued in a limited edition of gold, silver and conventional hard rubber, marks the beginning of...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...

at 03:30
Crossover Markets Group, Inc., a digital asset technology firm focused on meeting the unique liquidity requirements of institutions, today announced several key performance indicators from Q1 trading on its flagship digital assets platform CROSSx....



News published on and distributed by: